Blueshift Asset Management’s Akero Therapeutics AKRO Stock Holding History

Blueshift Asset Management’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,000	Closed	-$475K	–	459
2025 Q3	$475K	Buy	+10,000	New	+$484K	0.15%	210
2022 Q4	–	Sell	-5,942	Closed	-$202K	–	329
2022 Q3	$202K	Buy	+5,942	New	+$90.9K	0.04%	515

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Blueshift Asset Management's AKRO Position: Q4 2025 in Review

Blueshift Asset Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 10,000 shares — an estimated $475K sold.

Blueshift Asset Management first reported a position in AKRO in Q3 2022 and held it in 2 quarters. The position peaked at $475K in Q3 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Blueshift Asset Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Blueshift Asset Management sold 10,000 Akero Therapeutics shares in Q4 2025, an estimated $475K.
Blueshift Asset Management first reported a position in Akero Therapeutics in Q3 2022 and held it in 2 quarters.
Blueshift Asset Management's Akero Therapeutics position peaked at $475K in Q3 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Blueshift Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.